Rapid multiplexed genotyping for hereditary thrombophilia by SELDI-TOF mass spectrometry

Diagnostic Molecular Pathology

Volumn 19, Issue 1, 2010, Pages 54-61

  Yang, Shangbin ^a   Xu, Lihui ^a   Wu, Haifeng M ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Clotting disorder; Genotyping; Hereditary thrombophilia; SELDI TOF mass spectrometer; SNPs

Indexed keywords

DNA;

ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL LABORATORY; DISEASE PREDISPOSITION; DNA SEQUENCE; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; THROMBOPHILIA; THROMBOSIS;

CLINICAL LABORATORY TECHNIQUES; FACTOR V; GENOTYPE; HUMANS; MASS SPECTROMETRY; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTHROMBIN; THROMBOPHILIA;

EID: 77749334740     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3181a814bf     Document Type: Article

References (40)

1. Bezemer ID, Bare LA, Doggen CJ, et al. Gene variants associated with Deep vein thrombosis. JAMA. 2008;299:1306-1314.
2. Aiach M, Borgel D, Gaussem P, et al. Protein C and protein S Deficiencies. Semin Hematol. 1997;34:205-216.
3. Vinazzer H. Hereditary and acquired antithrombin Deficiency. Semin Thromb Hemost. 1999;25:257-263.
4. Coppens M, Van Mourik JA, Eckmann CM, et al. Current practise of testing for inherited thrombophilia. J Thromb Haemost. 2007;5:1979-1981.
5. Almawi WY, Tamim H, Kreidy R, et al. A case control study on the contribution of factor V-LeiDen, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of Deep venous thrombosis. J Thromb Thrombolysis. 2005;19:189-196.
6. McColl MD, Chalmers EA, Thomas A, et al. Factor V LeiDen, prothrombin 20210G-> A and the MTHFR C677T mutations in childhood stroke. Thromb Haemost. 1999;81:690-694.
7. Simioni P. Who should be tested for thrombophiliåCurr Opin Hematol. 2006;13:337-343.
8. Whitlatch NL, Ortel TL. Thrombophilias: when should we test and how does it help? Semin Respir Crit Care Med. 2008;29:25-39.
9. Xu B, Tubbs RR, Kottke-Marchant K. Molecular genetic testing of polymorphisms associated with venous thrombosis: a review of molecular technologies. Diagn Mol Pathol. 2005;14:193-202.
10. Kim S, Misra A. SNP genotyping: technologies and biomedical applications. Annu Rev Biomed Eng. 2007;9:289-320.
11. Tost J, Gut IG. Genotyping single nucleotiDe polymorphisms by MALDI mass spectrometry in clinical applications. Clin Biochem. 2005;38:335-350.
12. Humeny A, Bonk T, Berkholz A, et al. Genotyping of thrombotic risk factors by MALDI-TOF mass spectrometry. Clin Biochem. 2001;34:531-536.
13. Hung K, Sun X, Ding H, et al. A matrix-assisted laser Desorption/ ionization time-of-flight based method for screening the 1691G -> A mutation in the factor V gene. Blood Coagul Fibrinolysis. 2002;13:117-122.
14. Tang N, Tornatore P, Weinberger SR. Current Developments in SELDI affinity technology. Mass Spectrom Rev. 2004;23:34-44.
15. Meyer K, Fredriksen A, Ueland PM. High-level multiplex genotyping of polymorphisms involved in folate or homocysteine metabolism by matrix-assisted laser Desorption/ionization mass spectrometry. Clin Chem. 2004;50:391-402.
16. Ross P, Hall L, Smirnov I, et al. High level multiplex genotyping by MALDI-TOF mass spectrometry. Nat Biotechnol. 1998;16: 1347-1351.
17. Paracchini S, Arredi B, Chalk R, et al. Hierarchical high-throughput SNP genotyping of the human Y chromosome using MALDI-TOF mass spectrometry. Nucleic Acids Res. 2002;30:e27.
18. Misra A, Hong JY, Kim S. Multiplex genotyping of cytochrome p450 single-nucleotiDe polymorphisms by use of MALDI-TOF mass spectrometry. Clin Chem. 2007;53:933-939.
19. Chace DH, Kalas TA, Naylor EW. Use of tanDem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem. 2003;49:1797-1817.
20. Dooley KC. TanDem mass spectrometry in the clinical chemistry laboratory. Clin Biochem. 2003;36:471-481.
21. Venditti LN, Venditti CP, Berry GT, et al. Newborn screening by tanDem mass spectrometry for medium-chain Acyl-CoA Dehydrogenase Deficiency: a cost-effectiveness analysis. Pediatrics. 2003; 112:1005-1015.
22. Saugy M, Cardis C, Robinson N, et al. Test methods: anabolics. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:111-133.
23. Chace DH, DiPerna JC, Naylor EW. Laboratory integration and utilization of tanDem mass spectrometry in neonatal screening: a moDel for clinical mass spectrometry in the next millennium. Acta Paediatr Suppl. 1999;88:45-47.
24. Maurer HH. Multi-analyte procedures for screening for and quantification of drugs in blood, plasma, or serum by liquid chromatography-single stage or tanDem mass spectrometry (LC-MS or LC-MS/MS) releVant to clinical and forensic toxicology. Clin Biochem. 2005;38:310-318.
25. Eichhorst J, Etter M, Lepage J, et al. Urinary screening for methylphenidate (Ritalin) abuse: a comparison of liquid chromatography- tanDem mass spectrometry, gas chromatography-mass spectrometry, and immunoassay methods. Clin Biochem. 2004;37: 175-183.
26. Deventer K, Van Eenoo P, Delbeke FT. Screening for amphetamine and amphetamine-type drugs in doping analysis by liquid chromatography/ mass spectrometry. Rapid Commun Mass Spectrom. 2006;20:877-882. (Pubitemid 43326697)
27. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis. 2008;25: 45-51.
28. Gage B, Eby C, Johnson J, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326-331.
29. WaDelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2008;113:784-792.
30. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic Determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358:999-1008.
31. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 lossof- function polymorphism is a major Determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244-2247.
32. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic Determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
33. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
34. Jin M, Cataland SR, Bissell M, et al. A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser Desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry. J Thromb Haemost. 2006;4:333-338.
35. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers iDentified from serum proteomic analysis for the Detection of early stage ovarian cancer. Cancer Res. 2004;64:5882-5890.
36. Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorDers. Annu Rev Med. 2000;51: 169-185.
37. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epiDemiological studies. J Thromb Haemost. 2005;3:292-299.
38. Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med. 2007;131:872-884.
39. Hunt BJ, Shannon M, BeVan D, et al. Is a nihilistic attituDe to thrombophilia screening justified? Thromb Haemost. 2002;87:918.
40. Lowe G, Woodward M, Vessey M, et al. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb Haemost. 2000;83:530-535.